Anti-VEGF remains most expensive PBS drug
The Australian government spent $55 million more on anti-VEGF macular disease therapies in 2020-21 compared to the previous year, with ...
Tag: Pharmaceutical Benefits Scheme (PBS)
The Australian government spent $55 million more on anti-VEGF macular disease therapies in 2020-21 compared to the previous year, with ...